Thymosin Alpha-1 vs LL-37

A 28-amino-acid peptide originally isolated from the thymus gland. Approved in 30+ countries for hepatitis B/C and sepsis. Used off-label as a comprehensive immune modulator.

A human antimicrobial peptide produced by neutrophils and epithelial cells. Active against bacteria, fungi, viruses and biofilms. The leading antimicrobial-peptide candidate for clinical translation.

TA1 trains and optimises T-cell function, enhances NK cell activity, and modulates dendritic cell maturation. Sits at the junction of innate and adaptive immunity.

LL-37 disrupts microbial membranes through electrostatic interaction with negatively charged bacterial lipids. Also modulates the innate immune response and chemotaxis.

1.6 mg subcutaneous 2x per week

100–500 mcg daily (research protocols)

~2 hours

Short — typically dosed daily

Subcutaneous

Subcutaneous, Topical

investigational

research-only

£30 · £6.0/mg via Peptides UK

Not yet listed